Health Economics›Non-small cell lung cancer›EGFR-mutated, all lines of therapy

EGFR-mutated, all lines of therapy

Non-small cell lung cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Osimertinib monotherapy Variant #01	—	R 77 777	28d	~16.6 mo	~38.1 mo	~19	~R 1 477 762 PFS proxy · indirect	15
Afatinib monotherapy Variant #01	—	R 34 727	28d	~11.0 mo	~10.8 mo	~12	~R 416 729 PFS proxy · indirect	5
Cisplatin, Gefitinib, Pemetrexed Variant #01	—	R 9 643	28d	—	~35.0 mo	—	—	1
Gefitinib, Nedaplatin, Pemetrexed Variant #01 Partial	—	R 9 268	28d	—	~35.0 mo	—	—	1
Gefitinib monotherapy Variant #01	—	R 8 556	28d	~9.7 mo	~17.0 mo	~11	~R 94 111 PFS proxy · indirect	27
Icotinib monotherapy Variant #01 Partial	—	—	28d	~11.2 mo	—	~13	—	5

6 of 6 regimens shown